Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT05636384
Recruiting Not applicable

SupporTive Care At Home Research for Patients With Advanced Cancer (STAHR-cancer)

NCT05636384 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Hospital
Phase
Not applicable
Started
2022-07-25
Last updated
2022-12-05

Condition(s) studied

Malignant NeoplasmHome Care ServicesQuality of LIfeUnplanned Hospitalization

Investigational drug(s) / intervention(s)

Home-based care

Home-based care: Home-based medical care is based on a specialized home-based medical team approach, including following: 1. Specialized Home-Based Medical Team Approach 2. Initial Assessment and Education 3. Initial Home Visits and Education 4. Multidisciplinary Team Meeting 5. Regular Assessment After the Initial Visit

Study summary

To test the effects of home-based care on unplanned hospitalization within 6 months among advanced cancer patients with decreased performance status. Home-based care includes education for patients and their family caregivers, home visits by specialized home-based medical staff, and regular status check-ups.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Both the patient and their family caregiver must meet the criteria to be considered for this research. 1. Patient 1. A person who has an advanced-stage solid cancer diagnosis (ICD-10 code C00-C70); A person who is receiving or planning to receive cancer treatment 2. A person who meets one of the following conditions 1. Has been evaluated as having ECOG performance status 2 2. Has been evaluated as having ECOG performance status 1 and is over 70 years of age 3. A person who wishes to stay at home 4. A person whose family caregiver resides at home 5. A person who wishes to participate in the research 2. Family Caregiver 1. A family\* member of the patient \* Family: refers to the patient's spouse (including a common-law partner), descendants and their spouses up to the second degree, siblings and their spouses, and relatives and their spouses up to the eighth degree. 2. A person who meets one of the following conditions: 1. Lives with the patient (patient's household member) 2. Does not live with the patient, but visits the patient's home more than three times a week 3. A person who wants the patient to stay at home 4. A person who can communicate easily with medical staff 5. A person who wishes to participate in the research Exclusion Criteria: If either the patient or the family caregiver meets any one of these criteria, they are excluded from the study. 1. Patient 1. A person who cannot speak, hear, or read Korean 2. A person who is judged by a medical doctor to be unable to take part in this research due to extremely poor health 3. A person residing outside the range that can be visited by the respective medical institution (the conditions for distance are to be specified by each medical institution)\* \* This condition is not applicable for the control group. 4. A person who has used hospital- or home-type hospice and palliative care services 5. A person who is under the age of 19 2. Family Caregiver 1. A person who cannot speak, hear, or read Korean 2. A person who is judged by a medical doctor to be unable to take part in this research due to extremely poor health 3. A person under the age of 19

Primary outcome measure(s)

  • Unplanned hospitalization — within 6 months following enrollment
    1. admission to the enrolled hospital to treat unexpected symptoms or medical conditions (not including planned admission for chemotherapy or admission for planned surgery or intervention) 2. admission to a hospital other than the enrolled hospital 3. admission to a nursing hospital for a duration of less than 4 weeks.

Trial sites (6)

FacilityCityRegionStatus
Dongguk University Medical Center Goyang-si Gyeonggi-do Recruiting
Bundang CHA Hospital Seongnam-si Gyeonggi-do Recruiting
Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do Recruiting
Seoul National University Hospital Seoul South Korea Recruiting
Chung-Ang University Hosptial Seoul South Korea Recruiting
Kyung Hee University Hospital Seoul South Korea Recruiting

More Seoul National University Hospital trials in South Korea

Lung Cancer Surgery in Sarcopenia Patients With Old Age Active, not recruiting
Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION) Recruiting
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis Recruiting
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer Recruiting
Reduction of Remifentanil-related Complications Starting soon

Other trials for the same condition

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) Recruiting
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) Recruiting
Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients Recruiting
QOL and Mental Health Using APD With Remote Monitoring System Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05636384 on ClinicalTrials.gov ↗ ← All trials in South Korea